Influenza and COVID-19 in patients with cardiovascular outcomes and the role of vaccines in preventing adverse cardiovascular complications

Read full text Summarise with VIRAT
Authors: Zubair Akhtar
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cardiovascular disease (CVD) is the leading global cause of death, and individuals who experience an acute myocardial infarction (AMI) remain at substantial risk of subsequent events. There is growing evidence that respiratory viruses further increase risk in patients with established CVD. This thesis investigates the association between viral infections, particularly influenza and COVID-19, and cardiovascular outcomes, and examines vaccination as a potential intervention that may modify this risk. The thesis brings together evidence from high-income and resource-limited settings through a literature review and a series of epidemiological studies which include analyses of randomised trial data to evaluate whether the timing of influenza vaccination influences outcomes after AMI; a national case-control study assessing influenza vaccine effectiveness (VE) against cardiovascular hospitalisation during a severe Australian season in 2017; and observational cohorts from Bangladesh that quantify the cardiovascular burden of SARS-CoV-2 infection before vaccine availability and examine the survival benefit associated with COVID-19 vaccination in patients with pre-existing CVD. Collectively, the program of work characterises patterns of vaccine uptake, estimates effectiveness across diverse settings, and evaluates associated clinical endpoints. There was no significant difference in outcomes based on vaccination timing. In Australia, the influenza VE was 85% against cardiovascular hospitalisation. In Bangladesh, the final study found that the COVID-19 vaccinated patients had a better survival rate of 89.6% compared to 81.4% in unvaccinated patients. Furthermore, AMI was associated with higher mortality, having a hazard ratio (HR) of 1.74, while vaccination was associated with a protective effect, with HR of 0.55. The findings show that influenza vaccination substantially reduces cardiovascular hospitalisations, irrespective of timing, and that COVID-19 vaccination provides a significant survival advantage, with mortality notably lower among vaccinated individuals. Although SARS-CoV-2 infection has been linked to increased risk of adverse cardiac events, further study is still needed to clarify these associations in resource-constrained environments. Overall, this thesis highlights the adverse effects of viral infections on cardiovascular outcomes and supports vaccination as an evidence-based key protective strategy to mitigate risk in patients with pre-existing CVD.

Fields of Study & Subjects

Influenza Virus Research Studies Vaccine Coverage and Hesitancy SARS-CoV-2 and COVID-19 Research

Publication details

Journal / source
UNSWorks (UNSW Sydney)
Publication date
24 March 2026
Language
EN
Document type
Thesis